Publications by authors named "Samantha Brongiel"
Ann Pharmacother
February 2023
Article Synopsis
- Immune checkpoint inhibitors (ICIs) can cause gastrointestinal (GI) inflammatory side effects, known as immune-related adverse events (irAEs), which are typically treated with steroids, but some cases do not respond.
- This study analyzed the effectiveness of second-line treatments, like infliximab, vedolizumab, and adalimumab, in patients with steroid-refractory GI irAEs from 2011 to 2019.
- Findings show that most patients (89.7%) responded positively to these treatments, with an even higher resolution rate (94.4%) in those who started infliximab within 14 days of steroid treatment, typically resolving symptoms within about 17 days.
